Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 23;7(26):eabg4246. doi: 10.1126/sciadv.abg4246

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

PMC Copyright notice

Fig. 3 — (A) Illustrations representing trial types (ipsilateral and contralateral) of the delayed response task. (B and C) Chemogenetic silencing of the dlPFC-dCD (B) and dlPFC-MDl (C) pathways by local DCZ infusion into unilateral dCD (3 μl per site) and MDl (2 μl per site), respectively. (D) Behavioral effects of chemogenetic silencing of the unilateral dlPFC-dCD pathway for ipsilateral (left) and contralateral (right) trials [two-way ANOVA with treatment × delay; treatment; ipsilateral: Mk#1, F_(1,54) = 0.34, P = 0.56; Mk#2, F_(1,54) = 4.4, P = 0.04; contralateral: Mk#1, F_(1,54) = 35.8, P < 0.001; Mk#2, F_(1,54) = 7.4, P = 0.009; delay; ipsilateral: Mk#1, F_(2,54) = 11.8, P < 0.001; Mk#2, F_(2,54) = 12.6, P < 0.001; contralateral: Mk#1, F_(2,54) = 48.9, P < 0.001; Mk#2, F_(2,54) = 45.7, P < 0.001; interaction; ipsilateral: Mk#1, F_(2,54) = 1.1, P = 0.34; Mk#2, F_(2,54) = 1.8, P = 0.18; contralateral: Mk#1, F_(2,54) = 24.1, P < 0.001; Mk#2, F_(2,54) = 5.9, P = 0.005]. (E) Same as (D) but for silencing of the unilateral dlPFC-MDl pathway [treatment; ipsilateral: Mk#1, F_(1,54) = 3.0, P = 0.09; Mk#2, F_(1,54) = 1.0, P = 0.31; contralateral: Mk#1, F_(1,54) = 3.3, P = 0.07; Mk#2, F_(1,54) = 0.04, P = 0.84; delay; ipsilateral: Mk#1, F_(2,54) = 18.5, P < 0.001; Mk#2, F_(2,54) = 20.0, P < 0.001; contralateral: Mk#1, F_(2,54) = 12.8, P < 0.001; Mk#2, F_(2,54) = 17.5, P < 0.001; interaction; ipsilateral: Mk#1, F_(2,54) = 1.9, P = 0.16; Mk#2, F_(2,54) = 0.35, P = 0.71; contralateral: Mk#1, F_(2,54) = 0.98, P = 0.38; Mk#2, F_(2,54) = 0.04, P = 0.96]. Correct performance rate (means ± SEM, total of 10 sessions, five left and five right infusions for each target) following DCZ (ipsilateral, magenta; contralateral, purple) and vehicle infusions (cyan) are shown for two monkeys. Arrangements are the same as in Fig. 2.